• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

    2/10/22 4:05:00 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVS alert in real time by email

    Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company's results in greater detail.

    The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

    Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685.

    About Clovis Oncology

    Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the US, Europe, and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops with partners diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the US and Europe.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005865/en/

    Get the next $CLVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVS

    DatePrice TargetRatingAnalyst
    5/6/2022Buy → Neutral
    H.C. Wainwright
    9/21/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    8/5/2021$12.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

      Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the "Debtors") have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell their assets through a court supervised sales process. The Debtors have filed various "first day" motions with the Bankruptcy Court request

      12/12/22 12:18:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

      Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, "TRITON3: A Phase 3 Study of Rucaparib vs. Physician's Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)" is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, "Novel Clinical Trial Updates" at the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat. The presentation is available at https

      10/27/22 5:05:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

      Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose No serious adverse events, treatment discontinuations, or deaths related to 177Lu-FAP-2286 observed Confirmed partial response (PR) in one patient who completed the maximum six administrations of 177Lu-FAP-2286 in the 3.7 GBq dose cohort Patient continues without disease progression or subsequent anti-cancer therapy more than twelve months after first dose Stable disease (SD) in one heavily pretreated patient who completed four administrations of 177Lu-FAP-2286 in the 5.55 GBq dose coho

      10/17/22 3:45:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Clovis Oncology Inc.

      EFFECT - Clovis Oncology, Inc. (0001466301) (Filer)

      7/18/23 12:15:24 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Clovis Oncology Inc.

      15-12G - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:09:55 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clovis Oncology Inc.

      S-8 POS - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:05:29 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clovis Oncology downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Clovis Oncology from Buy to Neutral

      5/6/22 11:33:29 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      9/21/21 6:26:42 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      8/5/21 6:07:39 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Financials

    Live finance-specific insights

    See more
    • Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

      First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts in multiple tumor types anticipated in Q4 2022 Phase 3 ATHENA trial evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in front-line maintenance treatment of ovarian cancer presented at 2022 ASCO Annual Meeting Simultaneous publication in the Journal of Clinical Oncology (JCO) Presented at

      8/8/22 8:00:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

      Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615 International participants 646.

      7/20/22 4:00:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

      ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in ITT population Late-breaker data to be presented in oral session at 2022 ASCO Annual Meeting on Monday, June 6 Two additional top-line Phase 3 data read-outs for Rubraca expected in next 12 months with potential to address ovarian and prostate cancer patient populations Initial Phase 1 clinical data for targeted radiothera

      5/4/22 8:00:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      12/22/22 4:37:40 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      6/13/22 2:20:18 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Rolfe Lindsey converted options into 8,374 shares and sold $4,188 worth of shares (4,261 units at $0.98), increasing direct ownership by 4% to 113,691 units (tax withholding)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:14 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gross Paul Edward converted options into 10,248 shares and sold $4,649 worth of shares (4,730 units at $0.98), increasing direct ownership by 6% to 98,330 units (for tax liability)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:43 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ivers-Read Gillian C converted options into 8,374 shares and sold $3,618 worth of shares (3,681 units at $0.98), increasing direct ownership by 2% to 293,612 units to satisfy withholding obligation

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:37 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

      Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today. "I am very pleased to welcome Dr. Ronit Simantov to the Clovis Oncology Board of Directors, as she brings a wealth of expertise in oncology research and drug development to the role," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Dr. Simantov's extensive background and experience will support Clovis' key strategic priorities as we continue to advance both Rubraca's pipeline into a potentially broader label and the Company's early-stage pipeline of targeted radiotherapy candidates, including FAP-2286, into clinical development." Dr. Simanto

      7/12/21 4:05:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clovis Oncology Inc. (Amendment)

      SC 13G/A - Clovis Oncology, Inc. (0001466301) (Subject)

      2/10/23 9:48:18 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Clovis Oncology Inc.

      SC 13G - Clovis Oncology, Inc. (0001466301) (Subject)

      7/8/22 4:56:55 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clovis Oncology Inc. (Amendment)

      SC 13G/A - Clovis Oncology, Inc. (0001466301) (Subject)

      4/11/22 1:58:59 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care